Price
Financials
Standalone, Rs crore| Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | |
|---|---|---|---|---|---|---|
| Sales | 130 | 144 | 167 | 202 | 242 | 295 |
| Expenses | 99 | 113 | 123 | 156 | 183 | 222 |
| Operating Profit | 30 | 31 | 44 | 46 | 59 | 73 |
| OPM % | 23% | 21% | 26% | 23% | 24% | 25% |
| Other Income | 3 | 4 | 4 | 6 | 5 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 5 | 5 | 5 | 1 | 3 | 3 |
| Profit before tax | 28 | 30 | 43 | 50 | 61 | 76 |
| Tax % | 36% | 37% | 34% | 35% | 34% | 33% |
| Net Profit | 18 | 19 | 28 | 33 | 40 | 51 |
| EPS in Rs | ||||||
| Dividend Payout % | 17% | 22% | 72% | 27% | 41% | 25% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 18% | 21% | 22% | ||
| Compounded Profit Growth | % | 23% | 22% | 30% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | 32% | 33% | 34% |
| Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | |
|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 63 | 77 | 82 | 104 | 125 | 161 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 21 | 26 | 32 | 48 | 41 | 54 |
| Total Liabilities | 89 | 108 | 119 | 157 | 172 | 220 |
| Fixed Assets | 10 | 7 | 4 | 2 | 38 | 36 |
| CWIP | 0 | 0 | 0 | 35 | 0 | 0 |
| Investments | 7 | 14 | 40 | 17 | 16 | 37 |
| Other Assets | 72 | 87 | 74 | 103 | 118 | 148 |
| Total Assets | 89 | 108 | 119 | 157 | 172 | 220 |
| Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 17 | 15 | 27 | -7 | 70 | 27 |
| Cash from Investing Activity | -6 | -6 | -24 | 1 | -9 | -17 |
| Cash from Financing Activity | -3 | -4 | -19 | -12 | -15 | -12 |
| Net Cash Flow | 8 | 6 | -17 | -17 | 46 | -2 |
| Free Cash Flow | 17 | 14 | 24 | -34 | 59 | 26 |
| CFO/OP | 91% | 91% | 92% | 27% | 152% | 74% |
| Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | |
|---|---|---|---|---|---|---|
| Debtor Days | 36 | 36 | 36 | 33 | 24 | 19 |
| Inventory Days | 113 | 136 | 118 | 240 | 116 | 165 |
| Days Payable | 94 | 107 | 89 | 134 | 74 | 87 |
| Cash Conversion Cycle | 56 | 65 | 66 | 140 | 66 | 96 |
| Working Capital Days | 44 | 47 | 34 | 82 | 33 | 49 |
| ROCE % | 39% | 51% | 51% | 50% | 51% |
Fundamentals
Market Cap₹ Cr.
Current Price₹
Book Value₹
ROCE51.2 %
ROE34.4 %
Dividend Yield%
Face Value₹ 10.0
Compounded Sales Growth (TTM)22%
Compounded Profit Growth (TTM)30%
Standalone figures.
Profitability
Operating margin (excl. other income)21.27%
Operating margin (incl. other income)23.75%
EBITDA margin23.75%
Pre-tax margin20.50%
Net profit margin13.00%
ROE24.97%
ROCE39.43%
ROA18.95%
ROIC (approx.)45.65%
Tax rate36.57%
Other income / net worth4.34%
Growth
Sales growth (latest year)11.10%
Profit growth (latest year)2.80%
Per share
EPS (TTM)Rs 37.09
EPS (latest year)Rs 37.09
Book value per shareRs 162.50
Sales per shareRs 285.22
Cash flow per shareRs 29.11
Free cash flow per shareRs 51.49
Dividend per share (latest year)Rs 8.00
Dividends
Dividend payout21.57%
Efficiency
Asset turnover1.33x
Fixed asset turnover20.31x
Inventory turnover2.79x
Inventory days131 days
Debtor days36 days
Debtors turnover10.06x
Creditor days87 days
Cash conversion cycle96 days
Working capital days49 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 41 Cr
Net debtRs -41 Cr
Debt to equity0.00x
Net debt / EBITDA-1.20x
Interest coverage370.12x
Owners' fund to total sources75.68%
Debt to assets0.04%
Cash flow
Cash from Operating Activity (latest year)Rs 15 Cr
Cash from Investing Activity (latest year)Rs -6 Cr
Cash from Financing Activity (latest year)Rs -4 Cr
Net Cash Flow (latest year)Rs 6 Cr
Free cash flow (latest year)Rs 26 Cr
FCFE (approx.: FCF + change in debt)Rs 26 Cr
Cash from ops / profit, 5 years0.77x
Sales to cash flow9.80x
Statement figures
Net sales (TTM)Rs 144 Cr
Net sales (latest year)Rs 144 Cr
Operating profit excl. other income (latest year)Rs 31 Cr
Other income (TTM)Rs 4 Cr
EBITDA (TTM)Rs 34 Cr
PBDT (TTM)Rs 34 Cr
Profit before tax (TTM)Rs 30 Cr
Tax (latest year)Rs 11 Cr
Net profit (TTM)Rs 19 Cr
Net profit (latest year)Rs 19 Cr
Depreciation (TTM)Rs 5 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 66 Cr
Total expenditure (latest year)Rs 113 Cr
Total income (latest year)Rs 148 Cr
Share capitalRs 5 Cr
ReservesRs 77 Cr
Shareholders' fundsRs 82 Cr
Total assetsRs 108 Cr
Net blockRs 7 Cr
Capital work in progressRs 0 Cr
InvestmentsRs 14 Cr
ReceivablesRs 14 Cr
InventoryRs 24 Cr
Other liabilitiesRs 26 Cr
Shares outstanding (crore)0.51
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 4 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Solvay Pharma India Ltd(merged)?
Solvay Pharma India Ltd(merged) (532447) has a market capitalisation of Rs Cr. at the close.